Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial

BACKGROUND: Survival after resection of hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) still remains poor. Apatinib, a vascular endothelial cell growth factor receptor 2 inhibitor, has been shown to be safe and effective in patients with advanced HCC, so in the present study...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Hui-Chuan, Zhu, Xiao-Dong, Zhou, Jian, Gao, Qiang, Shi, Ying-Hong, Ding, Zhen-Bing, Huang, Cheng, Qiu, Shuang-Jian, Ren, Ning, Shi, Guo-Ming, Sun, Jian, Ye, Qing-Hai, Huang, Xiao-Wu, Yang, Xin-Rong, Fan, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661881/
https://www.ncbi.nlm.nih.gov/pubmed/33209881
http://dx.doi.org/10.21037/atm-20-6181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7661881/
https://www.ncbi.nlm.nih.gov/pubmed/33209881
http://dx.doi.org/10.21037/atm-20-6181

Ejemplares similares